Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. By inhibiting PP2A, the compound stimulates cell-cycle progression and interferes with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma.”
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://nnw.fm/LIXT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer